Prevention and early detection trials have been especially vulnerable to being disrupted by the COVID-19 lockdown, and a comparison of two regimens for monitoring pancreatic cysts—EA2185—was more vulnerable than most.
Prevention and early detection studies frequently require engaging physicians from specialties other than oncologists, said Peter O’Dwyer and Mitchell Schnall, co-chairs of ECOG-ACRIN Cancer Research Group.
Vinay Prasad might well have made his contrarian points without invoking the specter of the Third Reich. He didn’t have to go there—but he did. Voluntarily.
There is reason for concern about fascism rising in the United States. The reason is primarily Trumpism, followed by racism, followed by right-wing seditionist impulses.
Francis Collins will step down as director of NIH by the end of 2021, closing out a chapter in his career as the longest-serving presidentially appointed NIH director.
Thomas A. Waldmann, chief emeritus of the NCI Lymphoid Malignancies Branch and NIH Distinguished Investigator, died Sept. 25. He was 91.
Emil J Freireich, a trailblazing oncologist who developed groundbreaking therapies for childhood leukemia, and one of the 60 original members of ASCO, died Feb. 1.
Stand Up To Cancer (SU2C), Exact Sciences, and Providence announced funding for a new Dream Team dedicated to addressing colorectal cancer disparities. The SU2C Colorectal Cancer Health Equity Dream Team will receive a total of $8 million—$6 million from Exact Sciences and $2 million from Providence.
Michael Diaz was named president and managing physician at Florida Cancer Specialists and Research Institute.
Two Mount Sinai cancer researchers will be awarded $4 million in total costs from the National Institutes of Health Common Fund, which supports high-impact programs and research by junior scientists around the country.
